Sharma, A. ., Subudhi, S. ., Blando, J. ., Scutti, J. ., Vence, L. ., Wargo, J. ., … Sharma, P. . (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)

Ariyan, C. ., Brady, M. ., Siegelbaum, R. ., Hu, J. ., Bello, D. ., Rand, J. ., … Allison, J. . (2018). Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 6(2), 189-200. https://doi.org/10.1158/2326-6066.CIR-17-0356

Gao, J. ., Ward, J. ., Pettaway, C. ., Shi, L. ., Subudhi, S. ., Vence, L. ., … Sharma, P. . (2017). VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nature Medicine, 23(5), 551-555. https://doi.org/10.1038/nm.4308

Morris, V. ., Salem, M. ., Nimeiri, H. ., Iqbal, S. ., Singh, P. ., Ciombor, K. ., … Eng, C. . (2017). Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. The Lancet. Oncology, 18(4), 446-453. https://doi.org/10.1016/S1470-2045(17)30104-3